Resona Asset Management Co. Ltd. Has $75,000 Stake in Charles River Laboratories International, Inc. $CRL

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Resona Asset Management Co. Ltd. trimmed its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 96.9% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 479 shares of the medical research company's stock after selling 14,848 shares during the period. Resona Asset Management Co. Ltd.'s holdings in Charles River Laboratories International were worth $75,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of CRL. D1 Capital Partners L.P. acquired a new stake in Charles River Laboratories International during the fourth quarter worth about $172,752,000. Assenagon Asset Management S.A. grew its stake in Charles River Laboratories International by 1,721.1% during the first quarter. Assenagon Asset Management S.A. now owns 570,097 shares of the medical research company's stock worth $85,811,000 after buying an additional 538,792 shares in the last quarter. Nomura Holdings Inc. acquired a new stake in Charles River Laboratories International during the fourth quarter worth about $56,820,000. SG Americas Securities LLC boosted its stake in shares of Charles River Laboratories International by 16,153.2% in the 1st quarter. SG Americas Securities LLC now owns 267,202 shares of the medical research company's stock valued at $40,219,000 after purchasing an additional 265,558 shares in the last quarter. Finally, GAMMA Investing LLC grew its holdings in shares of Charles River Laboratories International by 24,226.8% during the 1st quarter. GAMMA Investing LLC now owns 210,427 shares of the medical research company's stock valued at $31,673,000 after purchasing an additional 209,562 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on CRL shares. Redburn Atlantic raised shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and decreased their price target for the company from $188.00 to $182.00 in a report on Friday, May 23rd. Robert W. Baird lifted their price target on shares of Charles River Laboratories International from $118.00 to $140.00 and gave the company a "neutral" rating in a report on Thursday, May 8th. Cowen raised shares of Charles River Laboratories International from a "hold" rating to a "buy" rating in a report on Wednesday, May 14th. JPMorgan Chase & Co. lifted their price target on shares of Charles River Laboratories International from $145.00 to $160.00 and gave the company a "neutral" rating in a report on Thursday, August 7th. Finally, Barclays lifted their price target on shares of Charles River Laboratories International from $155.00 to $165.00 and gave the company an "equal weight" rating in a report on Thursday, August 7th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $175.69.

Insider Activity

In other news, EVP Joseph W. Laplume sold 400 shares of the business's stock in a transaction that occurred on Thursday, August 7th. The shares were sold at an average price of $150.04, for a total value of $60,016.00. Following the transaction, the executive vice president owned 24,916 shares in the company, valued at approximately $3,738,396.64. The trade was a 1.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.30% of the company's stock.

Charles River Laboratories International Trading Up 0.4%

Shares of NYSE CRL opened at $157.27 on Tuesday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.10 and a current ratio of 1.36. Charles River Laboratories International, Inc. has a 52-week low of $91.86 and a 52-week high of $230.02. The firm has a 50 day moving average price of $157.06 and a two-hundred day moving average price of $148.69. The stock has a market cap of $7.74 billion, a P/E ratio of -118.25, a price-to-earnings-growth ratio of 5.00 and a beta of 1.48.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The medical research company reported $3.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.50 by $0.62. The firm had revenue of $1.03 billion during the quarter, compared to analysts' expectations of $983.76 million. Charles River Laboratories International had a negative net margin of 1.69% and a positive return on equity of 15.74%. The company's revenue was up .6% on a year-over-year basis. During the same period in the prior year, the company posted $2.80 EPS. As a group, equities analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.